First Trust中小型成长强度ETF FSGS 深 沪
已收盘 03-27 16:00:00 美东时间
28.4981
-0.562
-1.93%
华盛通- 最 高28.4981
- 今 开28.87
- 成交量 16股
- 最 低 28.4981
- 昨 收 29.0603
- 总市值 2707.33万
- 52周最高 32.0754
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 24.39
- 委 比 -60.00%
- 总股本 95.00万
- 历史最高 32.5669
- 量 比 0.02
- 振 幅 0.00%
- 历史最低 9.9631
- 每 手 1
- 风险率 1.43%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Maze Therapeutics' MZE829 Delivers First Clinical Proof-Of-Concept In APOL1-Mediated Kidney Disease With 61.8% Mean uACR Reduction In FSGS Subgroup
– At week 12, treatment with MZE829 resulted in a 35.6% mean uACR reduction in broad AMKD patients, 50% of the patients achieved a greater than 30% reduction in uACR, and treatment was well-tolerated –– The
03-25 19:09
Asia Fuel Oil-HSFO retains downside risk in ample supply
Asia Fuel Oil-HSFO retains downside risk in ample supply SINGAPORE, Feb 25 (Reuters) - Asia's high sulphur fuel oil (HSFO) market steadied on Wednesday after a recent pare-back, though downside risk still lingered amid expectations of ample supply. The prompt March-April timespread for 380-cst HSFO
02-25 18:11
Akebia’s Praliciguat FSGS Trial Moves Forward, Adding Optionality to the Kidney Pipeline
Akebia Therapeutics ($AKBA) announced an update on their ongoing clinical study...
02-11 00:30
2026美股生物科技板块怎么投资？杰富瑞：关注6大首选、7大潜力和5大并购目标
杰富瑞近日发布了关于 2026 年美股生物科技行业的展望报告，聚焦行业首选投资标的、被低估的潜力企业和潜在并购机会。
2025-12-25 15:40
Asia Fuel Oil-Spot differentials steady, HSFO cracks firm on volatile crude
SINGAPORE, Dec 17 (Reuters) - Spot differentials for the Asia fuel oil market were little changed on Wednesday, though high-sulphur fuel cracks inched higher amid volatile crude prices. Benchmarks for...
2025-12-17 18:30
BRIEF-Akebia Announces Establishment Of Rare Kidney Disease Pipeline
Dec 1 (Reuters) - Akebia Therapeutics Inc AKBA.O: AKEBIA ANNOUNCES ESTABLISHMENT OF RARE KIDNEY DISEASE PIPELINE AKEBIA THERAPEUTICS: ACQUIRES NEXT GENERATION TISSUE-TARGETED C3D-FACTOR H FUSION PROTE...
2025-12-01 21:21
Travere Therapeutics highlights advancements in rare kidney and metabolic disease therapies in new corporate overview
Travere Therapeutics Inc. has published a corporate presentation outlining its latest strategic priorities and milestones for 2025. The company highlighted its focus on rare kidney and metabolic disea...
2025-11-01 09:06
BUZZ-Needham ups Amicus Therapeutics to 'buy'
** Needham upgraded Amicus Therapeutics FOLD.O to "buy" from "hold", seeing company's current valuation as an attractive entry point ** Brokerage sees lower regulatory risk for DMX-200 after an FDA de...
2025-09-18 21:17
BRIEF-Travere Therapeutics Provides Update On FDA Advisory Committee Meeting For FILSPARI In FSGS
Sept 10 (Reuters) - Travere Therapeutics Inc TVTX.O: TRAVERE THERAPEUTICS PROVIDES UPDATE ON FDA ADVISORY COMMITTEE MEETING FOR FILSPARI® (SPARSENTAN) IN FSGS TRAVERE THERAPEUTICS INC - FDA NO LONGER ...
2025-09-10 19:55
Travere Therapeutics Announces Ongoing FDA Review for FILSPARI® in FSGS, Target Action Date Set for January 2026
Travere Therapeutics Inc. has announced that the U.S. Food and Drug Administration (FDA) has decided that an advisory committee meeting is no longer necessary for the review of the supplemental New Dr...
2025-09-10 19:01
